Adagene Inc (STU:978)

€ 2.52 -0.14 (-5.26%) Market Cap: 111.56 Mil Enterprise Value: 41.72 Mil PE Ratio: 0 PB Ratio: 2.07 GF Score: 32/100

Adagene Inc at HC Wainwright Investment Conference - New York Transcript
Sep 13, 2023
Adagene Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 11, 2023
Adagene Inc at EBD Group Biotech Showcase Transcript
Jan 09, 2023
Adagene Inc at Jefferies China Biotech Summit (Virtual) Transcript
Oct 26, 2021
Adagene Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 10, 2021

Adagene Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 11, 2023 / 08:15PM GMT

Release Date Price: €1.32 (+2.33%)

Transcript

Max Skor

Morgan Stanley - Analyst

Hi, everyone. Thank you for joining us. I'm Max Skor, a biotech analyst with Morgan Stanley. And before we get started, I just need to read an important disclosure. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at www.morganstanley.com/researchdisclosures. And if you have any questions, please reach out to your sales representative.

Great. Now, I'd like to welcome Peter Luo, CEO, and Ami Knoefler, Head of IR of Adagene. For those of us who are either new or revisiting the Adagene story, let's start off with a discussion of the target you're going after, the technology platform that's supporting your approach, and then future directions.

Questions & Answers

Max Skor;Peter Luo

Morgan Stanley - Analyst

So let's get started with CTLA-4 and why it's a good target for solid tumors.

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.